Puma Biotechnology, Inc. (PBYI) P/E Ratio History
UndervaluedTrading at 12.6x vs 5Y avg 213.2x · 57th percentile · Below historical baseline · Data 2022–2026
Loading P/E history...
P/E Ratio Analysis
As of June 23, 2026, Puma Biotechnology, Inc. (PBYI) trades at a price-to-earnings ratio of 12.6x, with a stock price of $7.66 and trailing twelve-month earnings per share of $0.48.
The current P/E is 94% below its 5-year average of 213.2x. Over the past five years, PBYI's P/E has ranged from a low of 3.5x to a high of 2820.0x, placing the current valuation at the 57th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, PBYI trades at a 43% discount to its sector peers. The sector includes 233 companies with P/E ratios ranging from 0.0x to 194.5x.
Relative to the broader market, PBYI trades at a notable discount to the S&P 500 median P/E of 24.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our PBYI DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
PBYI Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
PBYI P/E vs Peers
Oncology Therapeutics Developers peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $8B | 19.6 | - | +1747% | |
| $7B | 10.4 | - | +264% | |
| $4B | 9.6Lowest | - | +68% | |
| $13B | 18.5 | 0.36Best | +58% | |
| $143B | 18.4 | - | -4% | |
| $274B | 27.0 | 1.23 | +191% | |
| $90B | 19.4 | - | +49% | |
| $1B | 26.1 | 3.58 | +1883%Best |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
PBYI Historical P/E Data (2022–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | - | $6.39 | $0.48 | 13.4x | -94% |
| FY2025 Q4 | Dec 31 2025 | $5.95 | $0.61 | 9.8x | -95% |
| FY2025 Q3 | - | $5.31 | $0.74 | 7.2x | -97% |
| FY2025 Q2 | Jun 30 2025 | $3.43 | $0.98 | 3.5x | -98% |
| FY2025 Q1 | Mar 31 2025 | $2.96 | $0.77 | 3.9x | -98% |
| FY2024 Q4 | - | $3.05 | $0.61 | 5.0x | -98% |
| FY2024 Q3 | Sep 30 2024 | $2.55 | $0.48 | 5.4x | -97% |
| FY2024 Q2 | Jun 30 2024 | $3.26 | $0.19 | 17.5x | -92% |
| FY2024 Q1 | Mar 31 2024 | $5.30 | $0.33 | 16.3x | -92% |
| FY2023 Q4 | Dec 31 2023 | $4.33 | $0.45 | 9.5x | -96% |
| FY2023 Q3 | Sep 30 2023 | $2.63 | $0.07 | 35.2x | -83% |
| FY2023 Q1 | Mar 31 2023 | $3.09 | $0.11 | 27.6x | -87% |
| FY2022 Q4 | Dec 31 2022 | $4.23 | $0.00 | 2820.0x | +1223% |
| FY2022 Q3 | Sep 30 2022 | $2.37 | $0.22 | 10.7x | -95% |
Average P/E for displayed period: 213.2x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
4+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
PBYI — Frequently Asked Questions
Quick answers to the most common questions about buying PBYI stock.
What is PBYI's P/E ratio?
Puma Biotechnology, Inc. (PBYI) trailing twelve-month P/E ratio is 12.6x, based on TTM diluted EPS of $0.48. The 5-year average P/E is 213.2x and the historical range spans 3.5x to 2820.0x.
Is PBYI stock overvalued or undervalued?
PBYI trades at 12.6x P/E, below its 5-year average of 213.2x. At the 57th percentile of its historical range (3.5x–2820.0x), the stock is priced at a discount to its own history.
Is PBYI stock expensive?
No, PBYI is not expensive on a historical basis. The current P/E of 12.6x is below the 5-year average of 213.2x and sits at the 57th percentile of its valuation range.
What is PBYI's historical P/E range?
Over the past 5 years, PBYI's P/E ratio has ranged from 3.5x to 2820.0x, with a median of 10.7x and an average of 213.2x. The current P/E of 12.6x places the stock at the 57th percentile of this range. Full historical data spans 2022–2026.
How does PBYI's P/E compare to the S&P 500?
PBYI trades at 12.6x P/E versus the S&P 500 median of 24.3x. The 48% discount to the market suggests lower growth expectations or perceived higher risk.
How does PBYI's valuation compare to Healthcare peers?
Puma Biotechnology, Inc. P/E of 12.6x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is PBYI's PEG ratio?
PBYI PEG ratio is N/A, based on a P/E of 12.6x and EPS growth of -1.6%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is PBYI's earnings yield?
PBYI earnings yield is 7.96%, the inverse of its 12.6x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.